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Participants and Methods

Sampling Participants
Blood samples were collected in heparinised Eppendorf vessels (2ml) at regular time intervals over Seven human volunteers (4 m ales, 3 females; 2 days after administration by means of fingertip 4 fast acetylators and 3 slow acetylators o f sulfa-puncture with Monolet® lancets (Monoject, St
Vree et al.
Louis, USA). After centrifuging at 3000#, plasma samples were stored at -20°C pending analysis. Urine was collected upon untimed voiding. The total time of sample collection was 96 hours. Three samples (7ml) of each void were stored at -20°C pending analysis.
Sample Treatment
Plasma samples (100|il) were deproteinised with IOOjj.1 acetonitrile, centrifuged at 3000#, and 20 )lX1 o f the supernatant was injected onto the column.
Drug Analysis
Urlne Somptes
For the m easurem ent of N 4OH, urine was Sulfamethoxazole and all metabolites were an-centrifuged at 3000g, the supernatant was diluted alysed by direct HPLC analysis as described in de tail elsewhere.!151 1:9 with 0.2 mol/L KH2PO4 buffer pH 5.0, and 20ul was injected onto the column. 
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Protein Binding
The protein (in vitro)
For the measurement of sulfamethoxazole and the other metabolites, 50|il diethylamine was added to the urine sample of 7ml (pH 10) to in crease the solubility of all sulfonamides, centri fuged at 3000g, and thereafter the supernatant methoxazole and its metabolites was measured in was diluted 1:9 with 0.2 m ol/L K2PO4 buffer blank plasma samples by means of the Amicon pH 5-0.
Micropartition system M P S-1 (Grace BV, Amicon
Division, Capelle aan de IJssel, The Netherlands).
The average protein binding was calculated from 4 spiked-plasma samples, equilibrated for 15 min-
Intraday-lnterday Coefficient of Variation
The intraday and interday coefficients of variation of sulfamethoxazole and its metabolites were utes at 37°C. Minimal drug binding to the filters <5%.I,5I was observed.
Vive et al. 
Statistical Analysis
Table I summarises the mean ± SD values of the measured pharmacokinetic parameters o f sulfa methoxazole in the volunteers.
The lag time indicates the length of time elapsed before the appearance of a measurable plasma con centration of drug and metabolites. The average sequence of appearance in the blood was sulfa methoxazole 0.29 ± 0.41 hours, N4 at 0.48 ± 0.49 hours (p = NS), SOH at 0.74 ± 1.03 hours (p = NS), N4SOH at 1.11 ± 0.89 hours (p = 0.028), finally followed by Sgluc at 1.21 ± 1.00 hour (p = 0.049; p values compared with sulfamethoxazole.
The time at which the maximum concentration (Cmax) was reached (tmax) was the shortest for the parent drug (1.02 ± 0.84 hours), followed by that for Sgluc at 5.5 ± 3.4 hours (p = 0.0024), N4 at 6.9 Abbreviation: CV = coefficient of variation. The absorption half-life (t'/2abs) of sulfa-the compound is acetylated (88%); it decreases methoxazole was 0.12 ± 0.14 hours, which was when it is oxidised at the 5-position (40%). much shorter than that calculated for the metabo-Glucuronidation at the Ni-position reduces the lites. The t '/ 2abs of N4 (2.3 ± 0.9 hours) was identical protein binding to 20%. (1.3 ± 1.4 hours) . The same was observed for the formation of the hydroxy metabolites SOH (4.7 ± 5 .0 hours) and N4SOH (4.5 ± 2.4 hours; p = NS).
Regression lines, standard deviations, and anal-
(P NS) to that of Sgluc
The plasma elimination t'/2 varied between 9.6 and 1 1 hours (9.7 ± 1.3 hours) for the parent drug and metabolites. The t>/2 was slightly higher for Sgluc (15.2 ± 5.3 hours; p = 0.0352). The elimina tion t1 /-, derived from the renal excretion rate-time M curves for all compounds was identical to that of the N4~acetyl metabolite.
The mean residence times (MRT) of the meta bolites (20 to 25 hours) were higher than that o f the parent drug (14.4 ± 2.2 hours; p = 0.0044). The intrinsic mean residence time (MRTi), defined as MRTmeUiboIite-MRTparent drug, for N4 was 5.7 ± 1.9 hours (p = 0.0006), for Sgluc was 9.6 ± 7.6 hours Renal Clearance The intrinsic MRTij of N4SOH, when it was as sumed to be formed from N4, was 3.9 ± 1.9 hours, which did not differ significantly from the MRTi of N4-aceiylsulfamethoxazole (5.7 ± 1.9 hours). The highest apparent renal clearance was achieved with Sgluc with 176 ± 33 ml/min. When corrected for protein binding, the true renal clear ance was 240 ml/min. The renal clearance value of SOH was 96.1 ± 23.7 ml/min, which was signifi cantly lower than that for the Ni-glucuronide (pcO.OOOl). The renal clearance value of N4SOH was 51.2 ± 10.4 ml/min and for N4 was 35.2 ± 5.6 ml/min; these values were not significantly differ ent. When corrected for protein binding, the true renal clearance values of SOH and N4SOH were Adis international Limited, All rights reserved.
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Sulfamethoxazole had the lowest apparent renal clearance of 2.7 ± 0.9 ml/min and a true renal clear ance of 8.3 ml/min (table III) .
Discussion
Sulfamethoxazole is relatively well absorbed after oral administration. The percentage of the dose excreted in the urine as parent drug and metabolites varied between 70 and 90% J1*"I41 The lag time (tiag) gives the sequence of appearance in plasma and an indication regarding the dissolution rate and the absorption rate of the parent drug and the apparent rate of formation of the metabolites (tiag metabolite -tiag parent).
The tmax is also a hybrid parameter, determined by the processes of absorption or formation and the intrinsic rate of elimination. Absorption of sul famethoxazole is readily completed as the tmax oc curs at 1 hour; those of the primary conjugates (N4acetyl-, and Ni-glucuronide) occur at 5 to 7 hours. The oxidation to SOH and N4SOH proceeded at a slower rate but for a longer period; tmax was achieved at 10 hours.
The absorption half-life of the metabolites is a hybrid of the rates of formation and elimination. Like the tmax, this variable demonstrated that the rates of formation of N4-acetylation and N iglucuronidation were similar (p = 0.36), and as fast as the oxidation at the 5-position (p = 0.08). The Cmax and AUCo-00 values of N4 were 10 times higher than those of Sgluc. With equal absorp tion/formation rates and equal rates of elimination by renal clearance, it may suggest that the maxi mum velocity of the capacity-limited process (Vm ax) or the enzyme concentration of the Nacetylase(s) is 10 times higher than that of the N 1 -glucuronyltransferase(s).
The apparent elimination half-life of all meta clearance of sulfamethoxazole contributes notice ably to the overall oral clearance. When the Va of m / * * sulfamethoxazole was 10 hours, it was identical to that of the N4-acetyl metabolite. In the latter case the rate of acétylation of sulfamethoxazole governs the V /2 of both sulfamethoxazole and N4 (fig. 4) . These differences were observed within one sub ject, but did not reach statistical significance in the whole group of volunteers. The metabolites SOH and Sgluc demonstrated very small AUC values; the plasma concentrations were 5 to 10 times the quantitation limit. In these cases, the parallelism of the renal excretion rate-time profiles demonstrated the similarity of the half-lives. When the apparent plasma elimination halflives of the metabolites are identical to that of the parent drug, the total body clearances of the meta bolites are higher and the intrinsic MRT values must be smaller than that of the parent drug, which indeed was the case (table I) . Sulfamethoxazole is eliminated predominantly by metabolic conver sion into the metabolites, which in turn are elimi nated predominantly by renal excretion. The acetylator phenotype for sulfadimidine did not result in measurable differences in the percentage of the metabolite, nor in differences in the lives.11 14,21 ] Thus, in the in vivo situation an acetylator phenotype for sulfamethoxazole cannot be distinguished.*24! Sgluc and N4 showed the highest true renal clearance values as the result of glomerular filtra tion and active tubular secretion. All metabolites were excreted by active tubular secretion, as their renal clearance values exceeded the glomerular filtration rate. Furthermore, urine pH and urine flow have little effect on the renal clearance, and the renal clearance of N4 can be reduced by pro benecid comedication.112,'•'I The renal clearance bolites was similar, as has been demonstrated many of the metabolites equalled their total body cleartimes previously for sulfamethoxazole and its acyl ance, indicating that they were not further metabo metabolite.111_14' A slight variation in V/2 was ob-lised. The renal clearance of Sgluc was twice that served between sulfamethoxazole and N4, the Va of the calculated total body clearance, which may of sulfamethoxazole was 9 hours and that of N4 indicate that this glucuronide is synthesised in part was 10 hours. This occurred when the urine pH of by the human kidney, as previously reported for the the subject varied between pH 6 and 8, and renal methoxysulfonamidesJ16' 18!
